Durametrix LLC

Establishing the Market-readiness of an in Vivo Technology for Assessing Drug Toxicity-induced Tissue Damage - Project Summary There Is a Substantial and Growing Need for in Vivo Toxicity Testing, as in Drug R&D It Is Critical to Be Able to Understand Toxicity and to Identify and Eliminate Overly Toxic Candidates. We Developed an Imaging-based Approach That Detects Toxicity-induced Tissue Injury in a Minimally Invasive, Whole Body and Dynamic Fashion. the Goal of the Current Phase Ii STTR Grant Is to Expand the Marketability and Market Readiness of the Technology by Demonstrating a Broadened Scope of Utilities Including Semi-quantitative Characterization and Drug Safety. Overall, This in Vivo Imaging Approach Identifies an Important Marker for Drug Toxicity on a Personalized Basis With Objective and Quantitative Metric. the Early Detection of Drug Toxicity in Susceptible Tissues Will Help Make Timely Decisions in Drug R&D by Prioritizing Safe and Efficacious Candidates. the Technology Is Applicable to Multiple Stages in Pharmaceutical R&D and Is Expected to Generate a Significant Impact on Drug Development and Drug Safety.